Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APROCCHS: APC and Steroids in Septic Shock
NCT00625209Phase 3Completed
- Sponsor
- Université de Versailles Saint-Quentin-en-Yvelines
- Start
- Mar 2008
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of drotrecogin alfa, hydrocortisone and fludrocortisone in septic shock (4 arms), sponsored by Université de Versailles Saint-Quentin-en-Yvelines. Primary endpoint: 90-day mortality. Started Mar 2008; status: completed.
02
Drugs
drotrecogin alfahydrocortisonefludrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT00625209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625209.